DESFLURANE LIQUID
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
16-04-2020
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
DESFLURANE
Tillgänglig från:
BLUE-ZONE TECHNOLOGIES LTD
ATC-kod:
N01AB07
INN (International namn):
DESFLURANE
Dos:
100%
Läkemedelsform:
LIQUID
Sammansättning:
DESFLURANE 100%
Administreringssätt:
INHALATION
Enheter i paketet:
100
Receptbelagda typ:
Prescription
Terapiområde:
INHALATION ANESTHETICS
Produktsammanfattning:
Active ingredient group (AIG) number: 0128744001; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2020-04-17
Produktens egenskaper
_ _
_DESFLURANE (desflurane, USP)_
_ _
_ _
_ _
_ _
_ _
_ _
_Page _
1
_ of _
47
_ _
PRODUCT MONOGRAPH
PR
DESFLURANE
(desflurane, USP) 100% v/v
Liquid for Inhalation
Inhalation Anesthetic
Blue-Zone Technologies Ltd.
Concord, ON
Canada L4K 3C1
Date of Preparation:
April 16, 2020
SUBMISSION CONTROL NO: 199804
_ _
_DESFLURANE (desflurane, USP)_
_ _
_ _
_ _
_ _
_ _
_ _
_Page _
2
_ of _
47
_ _
TABLE OF CONTENTS
PRODUCT MONOGRAPH
.........................................................................................................1
TABLE OF CONTENTS
..............................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
..........................................................................................................
3
INDICATIONS AND CLINICAL
USE.................................................................................................................
3
CONTRAINDICATIONS
......................................................................................................................................
4
WARNINGS AND PRECAUTIONS
.....................................................................................................................
4
ADVERSE REACTIONS
.....................................................................................................................................
11
DRUG INTERACTIONS
.....................................................................................................................................
16
DOSAGE AND ADMINISTRATION
.................................................................................................................
18
OVERDOSAGE
....................................................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
.......................................................
Läs hela dokumentet
